Navigation Links
FDA Provides Cornerstone Pharmaceuticals Approval to Initiate Pivotal Study for CPI-613, its Metabolism-Directed Anticancer Compound
Date:3/23/2017

CRANBURY, N.J., March 23, 2017 /PRNewswire/ -- Cornerstone Pharmaceuticals, Inc., a clinical-stage, oncology-focused pharmaceutical company, announced a major milestone today.  Following successful End-of-Phase I (EOP1) Type B meetings with the U.S. Food and Drug Administration (FDA), the Company has been given a clear clinical and regulatory path forward to conduct pivotal trials of its lead compound, CPI-613, in patients with acute myeloid leukemia (AML) and pancreatic cancer.

CPI-613 is Cornerstone Pharmaceuticals' first-in-class anticancer compound from its proprietary Altered Energy Metabolism Directed (AEMD) platform. The drug is designed to disrupt the altered energy production pathways in cancer cells by targeting the mitochondrial tricarboxylic acid (TCA) cycle, an indispensable process essential to cell multiplication and survival. The FDA has designated CPI-613 an orphan drug for the treatment of acute myeloid leukemia (AML), pancreatic cancer and myelodysplastic syndromes (MDS).

"Our productive dialogue with the FDA has cleared a path forward for initiating pivotal trials of CPI-613, which may be sufficient to support our proposed indications for the treatment of AML and pancreatic cancer," said Sanjeev Luther, Chief Operating Officer, Cornerstone Pharmaceuticals. "The FDA has provided valuable feedback to inform a design that will enhance the robustness of our trials. This would allow the Agency to assess them as registrational trials. We are confident in our ability to meet the FDA's requirements for the trials, and look forward to continued interaction with the FDA as the CPI-613 clinical development program advances."

During the EOP1 Type B meetings with the FDA, Cornerstone Pharmaceuticals presented updated results from Phase I trials of CPI-613 in patients with AML and pancreatic cancer.

"We believe the Phase II trial in AML can potentially lead to approval for treatment of a disease that historically has been extremely difficult to treat," said Jorge Cortes, M.D., lead investigator of the AML trials and Deputy Chair and Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.

"We are encouraged that the FDA has granted us the opportunity to continue clinical trials in pancreatic cancer, a disease with large unmet clinical need, and are optimistic that we will continue to see positive results in advanced pancreatic cancer patients," commented Philip A. Philip, M.D., Ph.D., F.R.C.P., lead investigator of the pancreatic cancer trials and Professor of Oncology and Pharmacology, Leader, GI and Neuroendocrine Oncology, and Vice President of Medical Affairs at Karmanos Cancer Center, Wayne State University.

About Cornerstone Pharmaceuticals, Inc.

Cornerstone Pharmaceuticals, Inc. is a clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Cornerstone's primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Cornerstone's first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has designated CPI-613 an orphan drug for the treatment of acute myeloid leukemia (AML), pancreatic cancer and myelodysplastic syndromes (MDS). The company's investors include IDT Corporation (NYSE: IDT). For more information, visit www.cornerstonepharma.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements relate to future events or the company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Contact:
Jacob Jonas
Public Relations, Cornerstone Pharmaceuticals, Inc.
jacob@cornerstonepharma.com  

Kara Golub
JFK Communications, Inc.
609-456-0822
kgolub@jfkhealth.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fda-provides-cornerstone-pharmaceuticals-approval-to-initiate-pivotal-study-for-cpi-613-its-metabolism-directed-anticancer-compound-300428286.html


'/>"/>
SOURCE Cornerstone Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Update - Ampio Pharmaceuticals Provides Corporate Update
2. PTC Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
3. Marapharm Ventures Inc. "Marapharm" Provides Construction Updates for 13.6 Acres of Industrial Land and Buildings Located in Washington State and 7 Acres in Nevada
4. Pulmatrix Reports 2016 Financial Results; Provides 2017 Outlook on Pulmonary Disease Pipeline
5. ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
6. Mirati Therapeutics Reports Financial Results And Provides Business Update For The Fourth Quarter And Full Year 2016
7. Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and Provides Company Update
8. New convenient air-sampling device provides first-ever unique home allergen profiles
9. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results
10. Veracyte Announces Fourth Quarter and Full-Year 2016 Financial Results, Provides 2017 Financial Outlook
11. Halyard Health, Inc. Announces Fourth Quarter and Full-Year 2016 Results, Provides 2017 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... ... Steven C. Bilt, Chief Executive Officer of Smile Brands Inc. spoke about ... during a panel discussion at Dykema’s 6th Annual Definitive Conference for Dental Service Organizations ... Dallas, Texas. , Bilt co-founded Smile Brands Inc. in 1998 and has been instrumental ...
(Date:7/17/2019)... (PRWEB) , ... July 17, 2019 , ... As part ... Medical Center has added the Medtronic O-arm® Mobile Surgical Imaging System to lessen ... Director of The Minimally Invasive Brain and Spine Center at Mercy has ...
(Date:7/13/2019)... AUSTIN, Texas (PRWEB) , ... July 12, 2019 ... ... 3.5 million Americans’ ability to communicate and socialize with others. Given how widespread ... know someone on the spectrum! While autism cannot be “cured,” there are treatment ...
Breaking Medicine Technology:
(Date:7/13/2019)... ... July 12, 2019 , ... The ... County. The office is located at 5380 S. Rainbow Blvd., Suite 210, Las ... , The cancer center is equipped with state-of-the-art medical equipment plus all of ...
(Date:7/13/2019)... , ... July 12, 2019 , ... ... YCBD), has been named a “Brand to Watch” by Brightfield Group, a leading ... cbdMD in the top 10 of domestic CBD companies in two categories, Topicals ...
(Date:7/13/2019)... ... July 12, 2019 , ... The American Med Spa ... report is designed to help medical aesthetic and medical spa professionals understand the realities ... across the industry. , “It’s been two years since AmSpa released the 2017 Medical ...
(Date:7/12/2019)... ... July 12, 2019 , ... Rebecca Baxt, M.D., F.A.A.D. and Saida Baxt, M.D., ... 2019. Located in Paramus, BAXT CosMedical is a renowned facility that believes in honest ... for the past 45 years. , NJ Top Docs, Dr. Rebecca Baxt and Dr. ...
(Date:7/11/2019)... ... 11, 2019 , ... The International Society for Pharmaceutical ... of features to further advance their mission of delivering technical and operational solutions ... for patients worldwide. The latest additions include a new ISPE official video page, ...
Breaking Medicine News(10 mins):